Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.

Official Title

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

Keywords

Endometrial Cancer, Endometrial Carcinoma, Endometrium Cancer, Neoplasms Endometrial, Advanced, Metastatic, PD-1, PD-L1, retifanlimab, INCMGA0012, INCAGN02385, INCAGN02390, PODIUM, LAG-3, TIM-3, Endometrial Neoplasms, epacadostat, pemigatinib, retifanlimab + epacadostat, retifanlimab + pemigatinib, retifanlimab + INCAGN02385 and INCAGN02390

Eligibility

Locations

  • UCLA Medical Hematology & Oncology
    Los Angeles California 90048 United States
  • Olive View Med Ctr
    Sylmar California 91342 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Incyte Corporation
ID
NCT04463771
Phase
Phase 2 Endometrial Cancer Research Study
Study Type
Interventional
Participants
About 206 people participating
Last Updated